1
|
Ahouach B, Harent S, Ullmer A, Martres P, Bégon E, Blum L, Tess O, Bachmeyer C. Cutaneous lesions in a patient with COVID-19: are they related? Br J Dermatol 2020; 183:e31. [PMID: 32353170 PMCID: PMC7267646 DOI: 10.1111/bjd.19168] [Citation(s) in RCA: 59] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- B Ahouach
- Unité de dermatologie, Hôpital René Dubos, Pontoise, France
| | - S Harent
- Unité d'infectiologie, Hôpital René Dubos, Pontoise, France
| | - A Ullmer
- Unité de médecine interne, Hôpital René Dubos, Pontoise, France
| | - P Martres
- Laboratoire de microbiologie, Hôpital René Dubos, Pontoise, France
| | - E Bégon
- Unité de dermatologie, Hôpital René Dubos, Pontoise, France
| | - L Blum
- Unité de dermatologie, Hôpital René Dubos, Pontoise, France
| | - O Tess
- Service d'anatomopathologie, Hôpital René Dubos, Pontoise, France
| | - C Bachmeyer
- Service de médecine interne, Hôpital Tenon (AP-HP), Paris, France
| |
Collapse
|
2
|
Peiffer-Smadja N, Harent S, Messeca C, Lechapt-Zalcman E, Yazdanpanah Y, Joly V. A case of thoracic actinomycosis presenting as sudden paraplegia. Rev Neurol (Paris) 2018; 175:89-92. [PMID: 30309660 DOI: 10.1016/j.neurol.2018.01.380] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2017] [Revised: 01/15/2018] [Accepted: 01/16/2018] [Indexed: 11/18/2022]
Affiliation(s)
- N Peiffer-Smadja
- Hôpital Bichat-Claude-Bernard, Assistance publique-Hôpitaux de Paris, 75877 Paris, France; Inserm, IAME, UMR 1137, université Paris Diderot, 75870 Paris, France.
| | - S Harent
- Hôpital Bichat-Claude-Bernard, Assistance publique-Hôpitaux de Paris, 75877 Paris, France
| | - C Messeca
- Hôpital Bichat-Claude-Bernard, Assistance publique-Hôpitaux de Paris, 75877 Paris, France
| | - E Lechapt-Zalcman
- Centre Hospitalier Saint-Anne, Assistance publique-Hôpitaux de Paris, 75014 Paris, France
| | - Y Yazdanpanah
- Hôpital Bichat-Claude-Bernard, Assistance publique-Hôpitaux de Paris, 75877 Paris, France; Inserm, IAME, UMR 1137, université Paris Diderot, 75870 Paris, France
| | - V Joly
- Hôpital Bichat-Claude-Bernard, Assistance publique-Hôpitaux de Paris, 75877 Paris, France
| |
Collapse
|
4
|
Welfringer A, Vuong V, Argy N, Chochillon C, Deschamps L, Rollin G, Harent S, Joly V, Vindrios W, Descamps V. A rare fungal infection: Phaehyphomycosis due to Veronaea botryosa and review of literature. Med Mycol Case Rep 2017; 15:21-24. [PMID: 28217435 PMCID: PMC5300299 DOI: 10.1016/j.mmcr.2017.02.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2016] [Revised: 01/25/2017] [Accepted: 02/03/2017] [Indexed: 11/25/2022] Open
Abstract
We report a rare case of phaehyphomycosis in a 71-year-old heart transplant recipient Togo native patient. Four months after the transplant, he presented painless nodules on the right heel with superficial ulceration. The polyphasic identification uncovered a rare cause of phaehyphomycose: V. botryosa. The treatment combined surgical excision of the lesions and anti-fungal therapy with posaconazole. We discussed eleven reported cases in literature since 1990.
Collapse
Affiliation(s)
- Anne Welfringer
- Department of dermatology, Hospital Bichat, University Paris Diderot, Paris, France
| | - Valérie Vuong
- Department of dermatology, Hospital Bichat, University Paris Diderot, Paris, France
| | - Nicolas Argy
- Department of Parasitology-mycology, Hospital Bichat, University Paris Descartes, Paris, France
| | - Christian Chochillon
- Department of Parasitology-mycology, Hospital Bichat, University Paris Descartes, Paris, France
| | - Lydia Deschamps
- Department of Pathology, Hospital Bichat, University Paris Diderot, Paris, France
| | - Guillaume Rollin
- Department of Infectious diseases, Hospital Bichat, University Paris Diderot, Paris, France
| | - Stanislas Harent
- Department of Infectious diseases, Hospital Bichat, University Paris Diderot, Paris, France
| | - Véronique Joly
- Department of Infectious diseases, Hospital Bichat, University Paris Diderot, Paris, France
| | - William Vindrios
- Department of Infectious diseases, Hospital Bichat, University Paris Diderot, Paris, France
| | - Vincent Descamps
- Department of dermatology, Hospital Bichat, University Paris Diderot, Paris, France
| |
Collapse
|
5
|
Desnoyer A, Pospai D, Lê MP, Gervais A, Heurgué-Berlot A, Laradi A, Harent S, Pinto A, Salmon D, Hillaire S, Fontaine H, Zucman D, Simonpoli AM, Muret P, Larrouy L, Bernard Chabert B, Descamps D, Yazdanpanah Y, Peytavin G. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 2016; 65:40-47. [PMID: 26952005 DOI: 10.1016/j.jhep.2016.02.044] [Citation(s) in RCA: 141] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/06/2015] [Revised: 02/24/2016] [Accepted: 02/26/2016] [Indexed: 12/11/2022]
Abstract
BACKGROUND & AIMS Hepatitis C virus (HCV) infection is an independent risk factor for chronic kidney disease and leads to faster liver disease progression in patients requiring hemodialysis than in those with normal renal function. Little is known about the use of a sofosbuvir-containing regimen for infected patients on hemodialysis. We aimed to describe the pharmacokinetics, safety and efficacy of sofosbuvir in 2 dosing regimens and associated antiviral agents in HCV-infected patients requiring hemodialysis. METHODS Multicenter, prospective and observational study of patients receiving sofosbuvir, 400mg once daily (n=7) or 3 times a week (n=5), after hemodialysis with simeprevir, daclatasvir, ledipasvir or ribavirin was conducted. Drug plasma concentrations were determined by liquid chromatography-tandem mass spectrometry before and after a 4h hemodialysis and 1.5h after last drug intake at the end of hemodialysis. RESULTS Plasma concentrations of sofosbuvir or its inactive metabolite sofosbuvir-007 did not accumulate with either regimen between hemodialysis sessions or throughout the treatment course. Sofosbuvir-007 extraction ratio (52%) was consistent with historical data. In one patient receiving the once daily regimen, sofosbuvir-007 half-life was slightly higher (38h) than for patients with normal renal function receiving a full dose. Hemodialysis did not remove any other associated anti-HCV agents. Clinical and biological tolerance was good for all patients. Two relapses occurred with the 3 times a week regimen and none with the once daily. CONCLUSIONS A regimen including sofosbuvir, 400mg once daily, could be proposed for HCV-infected patients requiring hemodialysis and should be associated with close clinical, biological, cardiovascular, and therapeutic drug monitoring. LAY SUMMARY Hepatitis C Virus (HCV) infection in hemodialysis patients is prevalent and aggressive. Effective anti-HCV treatment in these patients may stabilize their renal disease. However, sofosbuvir, the cornerstone of most anti-HCV-containing regimens, should not be administered to these patients until more data is available. In this pharmacokinetic study, sofosbuvir full dose (400mg once daily) administered every day with another direct antiviral agent did not accumulate in hemodialysis patients and was safe and effective.
Collapse
Affiliation(s)
- Aude Desnoyer
- Pharmaco-Toxicology Department, Bichat-Claude Bernard Hospital, APHP, Paris, France.
| | - Dan Pospai
- Gastroenterology Department, Bichat-Claude Bernard Hospital, APHP, Paris, France
| | - Minh Patrick Lê
- Pharmaco-Toxicology Department, Bichat-Claude Bernard Hospital, APHP, Paris, France
| | - Anne Gervais
- Infectious Diseases & Tropical Department, Bichat-Claude Bernard Hospital, APHP, Paris, France
| | | | | | - Stanislas Harent
- Infectious Diseases & Tropical Department, Bichat-Claude Bernard Hospital, APHP, Paris, France
| | - Adriana Pinto
- Infectious Diseases & Tropical Department, Bichat-Claude Bernard Hospital, APHP, Paris, France
| | - Dominique Salmon
- Internal Medicine Department, Cochin Hospital, APHP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Sophie Hillaire
- Gastroenterology Department, Foch Hospital, Suresnes, France
| | - Hélène Fontaine
- Gastroenterology Department, Cochin Hospital, APHP, Paris Descartes University, Sorbonne Paris Cité, Inserm U1016, Paris, France
| | - David Zucman
- Infectious Diseases Department, Foch Hospital, Suresnes, France
| | | | - Patrice Muret
- Clinical Pharmaco-Toxicology Department, University Hospital of Besançon, INSERM U1098, Besançon, France
| | - Lucile Larrouy
- Virology Department, Bichat-Claude Bernard Hospital, APHP, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, IAME, INSERM UMR 1137, Paris, France
| | | | - Diane Descamps
- Virology Department, Bichat-Claude Bernard Hospital, APHP, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, IAME, INSERM UMR 1137, Paris, France
| | - Yazdan Yazdanpanah
- Infectious Diseases & Tropical Department, Bichat-Claude Bernard Hospital, APHP, Paris, France
| | - Gilles Peytavin
- Pharmaco-Toxicology Department, Bichat-Claude Bernard Hospital, APHP, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, IAME, INSERM UMR 1137, Paris, France
| |
Collapse
|